QLP2117, a Novel CCR8-Targeting Antibody Drug by Qilu Pharmaceutical, Enters Phase II Clinical Trials for Gastric and Lung Cancers

Oct 31, 2025 23:59 CST Updated 23:59

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

QLP2117 Injection is an innovative antibody drug independently developed by Qilu Pharmaceutical that targets CCR8. The product can simultaneously bind to CCR8 on the surface of Treg cells in tumors and FcγR on the surface of NK cells, mediating the direct killing of Treg cells by NK cells. By inhibiting the activity of Treg cells, it alleviates immunosuppression to enhance the killing of tumor cells.

Now, this new anti-cancer drug has finally officially launched clinical trials! Patients in China can now access it throughGlobal Oncology Doctors Network Medical Department (4006667998), understand the detailed inclusion and exclusion criteria, or preliminarily assess whether you qualify for participation.

Introduction to Anti-Cancer Projects

Drug Name：QLP2117；

Staging:Phase Ⅱ；

Line of Treatment:Standard Treatment FailureDefeat;

Mutated Gene:No Target Requirement。

Which patients are suitable?

Applicable to locally advanced unresectable, recurrent or metastatic gastric cancer, squamous cell carcinoma of the lung, and squamous cell carcinoma of the head and neck confirmed by histopathology.

Inclusion Criteria (Partial)

RecipientTesterMustMustSymbolCombinedInAll standards below must be met to enter this study:

1) Aged ≥18 years, male or female;

2）Patients with locally advanced unresectable, recurrent, or metastatic tumors confirmed by histopathology who have failed standard treatment or cannot tolerate standard treatment (medical records must detail the specific manifestations of intolerance), lack standard treatment, or for whom standard treatment is currently not applicable: including but not limited to gastric/gastroesophageal junction cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck, cervical cancer, esophageal cancer, urothelial carcinoma, colorectal cancer, melanoma, and breast cancer, etc. Note: Standard treatment is determined according to existing diagnosis and treatment guidelines, consensus, and standards. Failure of standard treatment is defined as radiologically confirmed disease progression or tumor recurrence/metastasis occurring during or within 6 months after treatment.

3）The researchers determined that there was at least one target lesion according to the RECIST v1.1 criteria (at least one evaluable lesion for Phase Ib).

4）Able to provide archived or fresh tumor tissue samples (for testing CCR8, FOXP3, PD-L1, CD8+ T cells, and NK cells).

Exclusion Criteria (Partial)

RecipientTestPatientStill neededRowExceptThe following discomfortMeet all the criteria for participation in this clinical study to be enrolled:

1）Have previously received treatment regimens targeting CCR8, including but not limited to monoclonal antibodies, bispecific antibodies, small molecule compounds, antibody-drug conjugates (ADCs), and cell therapy, among others.

2）Known subjects who have previously experienced severe allergic reactions to other monoclonal antibodies, or are allergic to any component of QLP2117 and QL2107 formulations.

3）Patients who have previously received immunotherapy leading to permanent discontinuation of the drug.

4）Received other clinical trial drugs or treatments within 4 weeks prior to the first dose.

5）Active autoimmune disease or history of autoimmune disease requiring systemic treatment within 2 years prior to enrollment (including but not limited to myasthenia gravis, systemic lupus erythematosus, interstitial pneumonia, uveitis, ulcerative colitis, autoimmune hepatitis, hypophysitis, systemic vasculitis, nephritis, hyperthyroidism, hypothyroidism, etc.) (Exceptions: hypothyroidism treated with a stable dose of thyroid replacement hormone, Type I diabetes treated with a stable dose of insulin, or vitiligo with only skin manifestations).

Project Implementation Region

The study is currentlyTo be carried out in regions such as Anhui. Specific details will be confirmed upon later consultation.

Summary of Required Documents to Submit

The materials that patients need to prepare and submit include:Pathology Report, Genetic Testing Report, Admission Record, Discharge Summary, CT/MRI Examination, Complete Blood Count, Liver and Kidney Function, Coagulation Function, Infectious Disease Screening, Electrocardiogram Reportetc.

Global Oncology Department温馨提示

If you wantParticipate in this itemClinical research, orFor more information about QLP2117, please contactGlobal Oncology Doctors Network Medical Department (400-666-7998), obtain more information about applications both in China and internationally, or apply directly. We commit to keeping all participants' personal information confidential and guarantee adherence to China's laws and regulations related to clinical research throughout the entire process.

#Ark Gene Treasure Plan#

"Ark Gene Treasure Plan" is a gene "treasure hunt" initiative launched by Global Cancer Doctors Network in collaboration with Cancer-Free Home, authoritative gene testing institutions, international pharmaceutical companies, and renowned cancer centers. This program aims to thoroughly explore the survival hopes indicated in each gene testing report, comprehensively interpret the gene testing reports for cancer patients, and match cancer patients with suitable newly approved drugs and ongoing clinical trials of investigational drugs on a global scale, providing patients with new survival opportunities as well as chances for free treatment with approved or unapproved new drugs!

Patients who wish to participate can send their genetic test reports and diagnostic reports electronically.Subsidiary or PhotographyPhotoSend to: doctor.huang@globecancer.com. Leave contact information in the email, and the Medical Department will contact you by phone within 1 working day after receiving and analyzing the report; or call directly.Global Oncology Doctors Network Medical Department (400-666-7998)Evaluation.

This article is original content from Global Oncologist Network. Reproduction is strictly prohibited without authorization.

Scan to Add Patient Group

Cancer Fighting News｜New Technologies｜New Drug Development｜Authoritative Experts

Join the group to receive free anti-cancer resources

Patient Concerns